In this column for The Wall Street Journal’s Think Tank, Drew Altman says debate about whether to keep or repeal the Cadillac tax is more than a debate between sound policy and good politics, there are strong substantive arguments on both sides.
- view as grid
- view as list
In this post for The JAMA Forum, the Kaiser Family Foundation’s Larry Levitt discusses UnitedHealth’s exit from Affordable Care Act marketplaces, the possibility of bigger premium increases in 2017, and why these challenges are unlikely to significantly affect long-term sustainability of the market and the law.
Drew Altman discusses how public opinion can change as health proposals move from the idea stage to real legislative debates in this Wall Street Journal Think Tank column.
This column was published as a Wall Street Journal Think Tank column on October 12, 2016. U.S. Uninsured Rate is At An All-Time Low, But The Public Doesn’t Know It Donald Trump derided the Affordable Care Act in the second presidential debate as a “total disaster.” One inarguable success…
In this column for The Wall Street Journal’s Think Tank, Drew Altman discusses the critical issues to look for and questions to ask about the U.S. House task force health reform outline due out this week.
In this Wall Street Journal Think Tank column, Drew Altman discusses the risks of full disclosure of presidential candidates’ health records, and considers a possible solution to the problem.
In this Wall Street Journal Think Tank column, Drew Altman discusses what may be the most important change in the American health system—hint it’s not the Affordable Care Act—which has occurred without much discussion.
In this Wall Street Journal Think Tank column, Drew Altman discusses the latest challenges faced by the Affordable Care Act (ACA) marketplaces and why they should be kept in perspective: “If Obamacare had bipartisan support, they would be treated much more like mundane implementation issues to be addressed by Congress than glaring headlines about Obamacare failure.”
In this Axios column, Drew Altman analyzes new poll findings which show how one issue breaks through the gridlock between Democrats and Republicans in health – the high cost of prescription drugs.
This inaugural Drew Altman column for Axios examines how the GOP House bill would impact deductibles for people who buy insurance in the non-group market. A KFF analysis for the column shows deductibles in a typical non-group plan would be about $1550 higher under the American Health Care Act compared to the Affordable Care Act.